Viela Bio Shares Rise 52% on $3.05 Billion Buyout by Horizon Therapeutics
Source: Streetwise Reports (2/1/21) Shares of Viela Bio traded higher after it was announced that the company entered into a definitive agreement to be acquired by Horizon Therapeutics for $53.00 per share. Prior to the opening of U.S. market for trading today, clinical-stage biotechnology firm Viela Bio Inc. (VIE:NASDAQ), which is focused on pioneering treatments for autoimmune and severe inflammatory diseases and Horizon Therapeutics Plc (HZNP:NASDAQ), announced that t...
Source: streetwisereports.com